BASF dedicates global dermatology lab
BASF announced the opening of a new global dermatology laboratory at 500 White Plains Road in Tarrytown NY. The lab will focus on topical formulations for the pharmaceutical market. Work will include basic research on skin irritation and allergy reactions to full formulations using BASF solubilizers and its broadened excipient portfolio. The laboratory will also support customers in developing new marketing concepts and solving formulation challenges.

BASF's dermatology laboratory in Tarrytown NY.
“With the investment in a laboratory concentrating only on the specific needs of the pharmaceutical industry, BASF will be able to focus on the unique challenges of effectively delivering drugs with topical formulations, thereby improving patient health,” said Daniele Piergentili, Vice President, BASF Pharma Ingredients and Services North America.
The lab will employ a newly formed dermatology team comprising of R&D Scientists, Technical Sales, Marketing and Product Management.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
MediGene announces corporate restructuring and aims to strengthen pipeline
NYU Langone Medical Center and School of Medicine - New York City, USA

University of Texas Health Science Center at San Antonio - San Antonio, USA
Immune system reveals new ways to treat brain disease and pain
Vibrations key to efficiency of green fluorescent protein - Charting femtosecond energy flow could aid redesign of molecules to improve light capture

First microarrayed 3D neuronal culture platform developed

AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus

64 human genomes as new reference for global genetic diversity - The new reference data provide an important basis: The aim is to estimate the individual risk of developing certain diseases such as cancer
Psilocybin eases existential anxiety in people with life-threatening cancer
Novartis Phase III study shows once-daily NVA237 is superior to placebo and similar to tiotropium in improving lung function in COPD - GLOW2 study shows NVA237 provides superior 24-hour bronchodilation to placebo (p
